Dr. Reddy's

Leading Practices

  • Dr. Reddy's has begun reporting on ATM-related activities and issues in an annual sustainability report, including some performance data and long- term future goals.
  • The company publicly states its commitments on specific ATM issues, such as stakeholder engagement, ethical marketing and promotional practices, quality standards and philanthropic activities in Index Countries.
  • The company has developed a FDC for cardiovascular disease named the 'Red Heart Pill' and is currently awaiting regulatory approval in India; Dr. Reddy's is the only company in the generic sector that is conducting adaptive research into non-communicable Index Diseases, based on an explicit Index Country need.

 

Changes Compared to Index 2008

  • Dr. Reddy's was not evaluated in Access to Medicine Index 2008.
  • In June 2009, Dr. Reddy's and GlaxoSmithKline entered into a strategic alliance targeting emerging markets. As per the agreement, Dr. Reddy's will manufacture over 100 branded pharmaceuticals in its product portfolio and GlaxoSmithKline will market and distribute them to various countries in Africa, the Middle East, Asia Pacific and Latin America.
  • In 2009, Dr. Reddy's initiated a pilot survey project in various rural areas in India, as a means to help them develop and market an exclusive portfolio for local needs, with a pricing policy that promotes both ATM and financial sustainability. While no further information is provided on this initiative, it appears that Dr. Reddy's is attempting to establish a more tailored ATM strategy to reach patients in varying social settings and circumstances within India.

 

Suggested Areas for Improvement

  • Despite annual reporting which covered some ATM initiatives, Dr. Reddy's level of transparency is low across all technical areas. Based on the limited disclosure on the company's actual ATM activities, its ATM strategy and performance are hard to evaluate and benchmark compared to peers.
  • Unlike sector peers such as Cipla and Ranbaxy; and with the exception of the polypill, Dr. Reddy's does not appear to conduct much adaptive R&D for Index Diseases (e.g. formulations for specific social segments, such as pediatrics, pregnant women, heat stable formulations, fixed-dose combinations – FDCs). 
  • ""
Home » Stakeholders » Generic Pharmaceuticals